BESTCOM (WUXI) BIOTECH CO., LTD. – Trademark Portfolio
Entity Type: 03
BESTCOM (WUXI) BIOTECH CO., LTD. holds 25 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 23 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include LEANGBB, PARADOXINE, and LAXOSTERONE. The owner is based in WUXI.
ROOM 502, NO. 5 ZHI HUI ROAD, HUISHAN
DISTRICT
WUXI , CN
Showing of trademarks Trademarks
Trademark Classifications
BESTCOM (WUXI) BIOTECH CO., LTD.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does BESTCOM (WUXI) BIOTECH CO., LTD. have?
BESTCOM (WUXI) BIOTECH CO., LTD. has 25 U.S. trademarks filed with the USPTO. Of these, 3 registered, 22 cancelled.
What trademark classes does BESTCOM (WUXI) BIOTECH CO., LTD. file in?
BESTCOM (WUXI) BIOTECH CO., LTD. files trademarks across 2 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 5 (Pharmaceuticals). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are BESTCOM (WUXI) BIOTECH CO., LTD.'s most well-known trademarks?
BESTCOM (WUXI) BIOTECH CO., LTD.'s registered trademark portfolio includes well-known marks such as LEANGBB, PARADOXINE, and LAXOSTERONE. These are among 3 currently registered trademarks in the portfolio.
What is BESTCOM (WUXI) BIOTECH CO., LTD.'s trademark registration success rate?
BESTCOM (WUXI) BIOTECH CO., LTD. has a 12% trademark registration rate, with 3 out of 25 resolved applications resulting in successful registration. Currently, 0 applications are pending review.